Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results

Nkarta, Inc. (NKTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights • NKX101 clinical update highlights encouraging antileukemic activity in patients with AML using fludarabine/cytarabine lymphodepletion regimen • NKX019 clinical data presented at EHA 2023 and ICML 2023 meetings • Clinical updates planned for NKX019 in the second half of 2023 and NKX101 in the first half of 2024 • Cash and cash equivalents of $302.2 million on June 30, 2023; cash runway anticipated to fund operations into 2025"
07/05/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Nkarta Appoints Alyssa Levin Chief Financial and Business Officer"
06/09/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "CERTIFICATE OF AMENDMENTOFRESTATED CERTIFICATE OF INCORPORATIONOF"
05/11/2023 8-K Quarterly results
Docs: "Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights • Clinical updates on track for NKX101 in second quarter of 2023 at a company-hosted event and NKX019 in second half of 2023 • Cash and cash equivalents of $332.1 million on March 31, 2023 • Cash runway anticipated to fund operations into 2025 SOUTH SAN FRANCISCO, Calif., May 11, 2023 -- Nkarta, Inc. , a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies, today reported financial results for the first quarter ended March 31, 2023. “Nkarta remains focused on the potential of donor-derived CAR NK cell products to broaden access to the transformative power of cell therapy for patients,” said Paul J. Hastings, CEO and President of Nkarta. &#x..."
03/16/2023 8-K Quarterly results
Docs: "Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights • Clinical updates on track for NKX101 in first half of 2023 and NKX019 in full year 2023 • 2022 year-end cash and cash equivalents of $354.9 million • Cash runway anticipated to fund operations into 2025 SOUTH SAN FRANCISCO, Calif., March 16, 2023 -- Nkarta, Inc. , a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today reported financial results for the fourth quarter and year ended December 31, 2022. “Clinical data from our co-lead pipeline candidates have highlighted the promise of our allogeneic NK cell therapy technology to lead the next wave of cell therapy,” said Paul J. Hastings, President and C..."
01/09/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Nkarta Promotes David R. Shook, M.D., to Chief Medical Officer SOUTH SAN FRANCISCO, Calif., January 9, 2023 -- Nkarta, Inc. , a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced the promotion of David R. Shook, M.D., to the role of Chief Medical Officer. Dr. Shook has extensive expertise in cell therapy development and continues to lead Nkarta’s global clinical development and regulatory operations. “Dave has been a driving force behind the development and execution of Nkarta’s clinical strategy using off-the-shelf NK cell therapeutics since he joined our organization,” said Paul J. Hastings, President and CEO of Nkarta. “His expertise in the biology and engineering of NK cells, clinical develo..."
12/05/2022 8-K Quarterly results
12/02/2022 8-K Quarterly results
11/09/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
04/28/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "13,333,334 Shares of Common Stock NKARTA, INC. Common Stock UNDERWRITING AGREEMENT April 25, 2022 Cowen and Company, LLC SVB Securities LLC Evercore Group L.L.C. As Representatives of the several Underwriters c/o Cowen and Company, LLC New York, New York 10022 c/o SVB Securities LLC 53 State Street, 40th Floor Boston, Massachusetts 02109 c/o Evercore Group L.L.C. 55 East 52nd Street New York, New York 10055"
04/25/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs",
"Clinical Program Update Presentation, dated April 2022"
04/22/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Nkarta to Host Conference Call Highlighting Preliminary Clinical Data from Two Lead NK Cell Therapy Candidates Call scheduled for Monday, April 25, 2022 8:00 a.m. ET Clinical trial investigators to participate"
03/29/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Nkarta Appoints Manufacturing Technology Executive, Angela Thedinga, to Board of Directors Appointment brings extensive operational expertise in supply chain and novel commercial-scale manufacturing systems SOUTH SAN FRANCISCO, Calif. – Mar. 29, 2022 – Nkarta, Inc. , a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced today the appointment of Angela M. Thedinga, MBA, MPH, to its Board of Directors. “The speed of manufacturing innovation in cell and gene therapies in recent years has accelerated significantly. Angela is one of a handful of people who have been at the center of this activity,” said Paul J. Hastings, President and CEO of Nkarta. “Her expertise and insight in technical operations, supply..."
03/17/2022 8-K Quarterly results
Docs: "Nkarta Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights • On track to announce initial Phase 1 clinical trial data from two co-lead programs in 2022 – 1H 2022 - NKX101, a CAR NK cell therapy candidate engineered with NKG2D receptor, in relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic syndrome – FY 2022 - NKX019, a CAR NK cell therapy candidate engineered with CD19 receptor, in relapsed/refractory B cell malignancies SOUTH SAN FRANCISCO, Calif., March 17, 2022 -- Nkarta, Inc. , a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today reported financial results for the fourth quarter and year ended December 31, 2021. “2021 was a year of solid execution for ..."
11/10/2021 8-K Quarterly results
Docs: "Nkarta Reports Third Quarter 2021 Financial Results and Business Update"
10/22/2021 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Fourth Amendment to Lease, by and between HCP Life Science REIT, Inc. and Nkarta, Inc"
10/07/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Nkarta Announces Updates to NKX019 and NKX101 Clinical Development Programs"
08/12/2021 8-K Quarterly results
Docs: "Nkarta Reports Second Quarter 2021 Financial Results and Business Progress"
07/14/2021 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Lease, by and between HCP BTC, LLC and Nkarta, Inc",
"Nkarta Establishes New Combined NK Cell Therapy Manufacturing Facility / Company Headquarters"
06/15/2021 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/13/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
04/28/2021 8-K Quarterly results
03/25/2021 8-K Quarterly results
01/19/2021 8-K Quarterly results
01/13/2021 8-K Quarterly results
11/12/2020 8-K Quarterly results
Docs: "Cash and Cash Equivalents: As of September 30, 2020, Nkarta had cash, cash equivalents, restricted cash and short-term investments of $330.2 million, which includes proceeds from the Company’s July 2020 IPO of $265.1 million, net of underwriting discounts and commissions and other offering costs. • R&D Expenses: Research & development expenses were $9.8 million for the third quarter of 2020, which includes $0.7 million of non-cash stock-based compensation expense. • G&A Expenses: General and administrative expenses were $3.9 million for the third quarter of 2020, which includes $0.9 million of non-cash stock-based compensation expense. • Net Loss. Net loss was $13.7 million, or $0.44 per basic and diluted share, for the quarter ended September 30, 2020. Financial Guida...",
"Nkarta Announces Treatment of First Patient in First-in-Human Clinical Trial of Engineered NKG2D‑Based NK Cell Cancer Immunotherapy NKX101"
10/05/2020 8-K Quarterly results
08/20/2020 8-K Quarterly results
07/14/2020 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy